Safety outcomes associated with the moderna COVID-19 vaccine (mRNA-1273): a literature review

References

• Shi Y, Wang G, Cai X-P, et al. An overview of COVID-19. J Zhejiang Univ Sci B. 2020;21(5):343–360.
   PubMed Web of Science ®Google Scholar
• WHO. Coronavirus disease (COVID-19) pandemic. WHO; 2022 [cited 2022 Nov 15]. Available from: https://www.who.int/europe/emergencies/situations/covid-19
   Google Scholar
• WHO. COVID-19 advice for the public: getting vaccinated. WHO; 2022 [cited 2022 Nov 15]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice
   Google Scholar
• NHS. Coronavirus (COVID-19) symptoms in adults: crown; 2022 [ updated 24/10/22; cited 2022 Nov 15]. Available from: https://www.nhs.uk/conditions/coronavirus-covid-19/symptoms/main-symptoms/
   Google Scholar
• Census2021. COVID-19 data per age group: office of national statistics. 2021 [cited 2022 Nov 17]. Available from: https://www.ons.gov.uk/aboutus/transparencyandgovernance/freedomofinformationfoi/covid19dataperagegroup
   Google Scholar
• NICE. COVID-19 rapid guideline: managing. COVID-19: NICE; 2022 [cited 2022 Dec 2]. Available from: https://www.nice.org.uk/guidance/ng191/resources/covid19-rapid-guideline-managing-covid19-pdf-51035553326
   Google Scholar
• NHS. Coronavirus (COVID-19) vaccine: crown; 2022 [ updated 24/10/22; cited 2022 Dec 2]. Available from: https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/
   Google Scholar
• WHO. Coronavirus disease (COVID-19): vaccines: wHO; [ updated 16/03/22; cited 2022 Nov 17]. Available from: https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-covid-19-vaccines
   Google Scholar
• EMA. Safety of COVID-19 vaccines: European medicines agency; 2022 [cited 2022 Nov 20]. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/safety-covid-19-vaccines
   Google Scholar
• Schoenmaker L, Witzigmann D, Kulkarni JA, et al. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int J Pharm. 2021 May 15;601:120586. DOI:10.1016/j.ijpharm.2021.120586
   PubMedGoogle Scholar
• El Sahly HM, Baden LR, Essink B, et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med. 2021 Nov 4;385(19):1774–1785. DOI:10.1056/NEJMoa2113017
   PubMed Web of Science ®Google Scholar
• Mathieu E, Ritchie H, Rodés-Guirao L, et al. Coronavirus (COVID-19) vaccinations: our world in data. 2020 [ updated 28/11/22; cited 2022 Nov 20]. Available from: https://ourworldindata.org/covid-vaccinations
   Google Scholar
• Monte LM Who are the adults not vaccinated against COVID?: United States Census Bureau. 2021 [ updated 12/04/22; cited 2022 Nov 18]. Available from: https://www.census.gov/library/stories/2021/12/who-are-the-adults-not-vaccinated-against-covid.html
   Google Scholar
• Kadali RAK, Janagama R, Peruru S, et al. Non-life-threatening adverse effects with COVID-19 mRNA-1273 vaccine: a randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms. J Med Virol. 2021 Jul;93(7):4420–4429.
   PubMed Web of Science ®Google Scholar
• Lee DS, Kim JW, Lee KL, et al. Adverse events following COVID-19 vaccination in South Korea between February 28 and August 21, 2021: a nationwide observational study. Int J Infect Dis. 2022 May;118:173–182.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021 Feb 4;384(5):403–416.
   PubMed Web of Science ®Google Scholar
• Chu L, McPhee R, Huang W, et al. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine. 2021 May 12;39(20):2791–2799. DOI:10.1016/j.vaccine.2021.02.007
   PubMed Web of Science ®Google Scholar
• EMA. Spikevax (previously COVID-19 vaccine moderna): European medicines agency; 2022 [cited 2022 Nov 20]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/spikevax#safety-updates-section
   Google Scholar
• Anderson EJ, Creech CB, Berthaud V, et al. Evaluation of mRNA-1273 vaccine in children 6 months to 5 years of age. N Engl J Med. 2022 Nov 3;387(18):1673–1687. DOI:10.1056/NEJMoa2209367
   PubMed Web of Science ®Google Scholar
• Creech CB, Anderson E, Berthaud V, et al. Evaluation of mRNA-1273 covid-19 vaccine in children 6 to 11 years of age. N Engl J Med. 2022 May 26;386(21):2011–2023. DOI:10.1056/NEJMoa2203315
   PubMed Web of Science ®Google Scholar
• BP M, Saelee R. COVID-19 vaccination coverage among adolescents aged 12–17 years: mMWR Morb Mortal Wkly Rep; 2021 [ updated 02/09/21; cited 2022 Nov 20]. Available from: https://www.cdc.gov/mmwr/volumes/70/wr/mm7035e1.htm
   Google Scholar
• Ali K, Berman G, Zhou H, et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. N Engl J Med. 2021 Dec 9;385(24):2241–2251. DOI:10.1056/NEJMoa2109522
   PubMed Web of Science ®Google Scholar
• Kabisch M, Ruckes C, Seibert-Grafe M, et al. Randomized controlled trials: part 17 of a series on evaluation of scientific publications. Dtsch Arztebl Int. 2011 Sep;108(39):663–668.
   PubMed Web of Science ®Google Scholar
• Valiathan R, Ashman M, Asthana D. Effects of ageing on the immune system: infants to elderly. Scand J Immunol. 2016 Apr;83(4):255–266.
   PubMed Web of Science ®Google Scholar
• Masuda T, Murakami K, Sugiura K, et al. A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: an interim report. Vaccine. 2022;40(13):2044–2052. DOI:10.1016/j.vaccine.2022.02.030
   PubMed Web of Science ®Google Scholar
• Aryal S. Hypersensitivity- definition, causes, mechanism, types, examples: microbe notes; 2022 [cited 2022 Nov 19]. Available from: https://microbenotes.com/hypersensitivity-introduction-causes-mechanism-and-types/#causes-of-hypersensitivity
   Google Scholar
• Delves PJ Effects of aging on the immune system: MSD; 2021 [ updated 09/2022; cited 2022 Nov 20]. Available from: https://www.msdmanuals.com/home/immune-disorders/biology-of-the-immune-system/effects-of-aging-on-the-immune-system#top
   Google Scholar
• Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020 Dec 17;383(25):2427–2438. DOI:10.1056/NEJMoa2028436
   PubMed Web of Science ®Google Scholar
• Moro PL, Olson CK, Clark E, et al. Post-authorization surveillance of adverse events following COVID-19 vaccines in pregnant persons in the vaccine adverse event reporting system (VAERS), December 2020 - October 2021. Vaccine. 2022 May 26;40(24):3389–3394. DOI:10.1016/j.vaccine.2022.04.031
   PubMed Web of Science ®Google Scholar
• du Fosse NA, van der Hoorn MP, van Lith JMM, et al. Advanced paternal age is associated with an increased risk of spontaneous miscarriage: a systematic review and meta-analysis. Hum Reprod Update. 2020 Sep 1;26(5):650–669. DOI:10.1093/humupd/dmaa010
   PubMed Web of Science ®Google Scholar
• Sadarangani M, Soe P, Shulha HP, et al. Safety of COVID-19 vaccines in pregnancy: a Canadian National Vaccine Safety (CANVAS) network cohort study. Lancet Infect Dis. 2022 Nov;22(11):1553–1564.
   PubMed Web of Science ®Google Scholar
• Mor G, Cardenas I. The immune system in pregnancy: a unique complexity. Am J Reprod Immunol. 2010 Jun;63(6):425–433.
   PubMed Web of Science ®Google Scholar
• Coronavirus (COVID-19) and cancer: cancer research UK [ updated 30/09/22; cited Jun Nov 27]. Available from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/coronavirus/covid-19-and-cancer
   Google Scholar
• Coronavirus (COVID-19) vaccine and cancer: cancer research UK [ updated 03/10/22; cited 2022 Nov 27]. Available from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/coronavirus/covid-19-vaccine-and-cancer
   Google Scholar
• Jiménez Ortega AF, de Luna Aguilar A, Benitez Fuentes JD, et al. Adverse drug reactions of the SARS-CoV-2 mRNA-1273 vaccine in a cohort of cancer patients of a tertiary hospital in Madrid, Spain. J Clin Oncol. 2022;40(16_suppl):e24072. DOI:10.1200/JCO.2022.40.16_suppl.e24072
   Web of Science ®Google Scholar
• Oosting SF, van der Veldt AAM, GeurtsvanKessel CH, et al. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. Lancet Oncol. 2021 Dec;22(12):1681–1691.
   PubMed Web of Science ®Google Scholar
• NICE. Risk assessment for Venous Thromboembolism (VTE): Department of Health 2010 [cited 2022 Nov 27]. Available from: https://www.nice.org.uk/guidance/ng89/resources/department-of-health-vte-risk-assessment-tool-pdf-4787149213
   Google Scholar
• Mulder FI, Horvath-Puho E, van Es N, et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood. 2021 Apr 8;137(14):1959–1969. DOI:10.1182/blood.2020007338
   PubMed Web of Science ®Google Scholar
• ECOG performance status scale: eCOG-ACRIN cancer research group 2022 [cited 2022 Nov 27]. Available from: https://ecog-acrin.org/resources/ecog-performance-status/
   Google Scholar
• EMA. COVID-19 vaccines safety update: European medicines agency 2022 [cited 2022 Nov 20]. Available from: https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-10-november-2022_en.pdf
   Google Scholar
• Wong KK, Heilig CM, Hause A, et al. Menstrual irregularities and vaginal bleeding after COVID-19 vaccination reported to v-safe active surveillance, USA in December, 2020-January, 2022: an observational cohort study. Lancet Digit Health. 2022 Sep;4(9):e667–675.
   PubMedGoogle Scholar
• OASH. Your menstrual cycle: office on women’s health; 2021 [ updated 22/02/21; cited 2022 Nov 22]. Available from: https://www.womenshealth.gov/menstrual-cycle/your-menstrual-cycle
   Google Scholar
• Thiyagarajan DK, Basit H, Jeanmonod R. Physiology, menstrual cycle: StatPearls; [ updated 30/10/22; cited 2022 Nov 22]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK500020/
   Google Scholar
• Leon R, Richard J, Galea L Menstrual irregularities and the COVID-19 vaccine: The University of British Columbia 2021 [cited 2022 Nov 22]. Available from: https://womenshealthresearch.ubc.ca/blog/menstrual-irregularities-and-covid-19-vaccine#
   Google Scholar
• Edelman A, Boniface ER, Benhar E, et al. Association between menstrual cycle length and coronavirus disease 2019 (COVID-19) vaccination: a U.S. Cohort Obstet Gynecol. 2022 Apr 1;139(4):481–489. DOI:10.1097/AOG.0000000000004695
   PubMed Web of Science ®Google Scholar
• Foltran D, Delmas C, Flumian C, et al. Myocarditis and pericarditis in adolescents after first and second doses of mRNA COVID-19 vaccines. Eur Heart J Qual Care Clin Outcomes. 2022 Mar 2;8(2):99–103. DOI:10.1093/ehjqcco/qcab090
   PubMed Web of Science ®Google Scholar
• Massari M, Spila Alegiani S, Morciano C, et al. Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: a multi-database, self-controlled case series study. PLOS Med. 2022 Jul;19(7):e1004056. DOI:10.1371/journal.pmed.1004056
   PubMed Web of Science ®Google Scholar
• Husby A, Hansen JV, Fosbol E, et al. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study. BMJ. 2021 Dec 16;375:e068665. DOI:10.1136/bmj-2021-068665
   PubMedGoogle Scholar
• Wu KC, Deshpande SR Myocarditis: bMJ; 2022 [cited 2022 Nov 26]. Available from: https://bestpractice.bmj.com/topics/en-gb/244
   Google Scholar
• Gilotra NA. Myocarditis: Johns Hopkins 2022 [cited 2022 Nov 26]. Available from: https://www.hopkinsmedicine.org/health/conditions-and-diseases/myocarditis
   Google Scholar
• Kyto V, Sipila J, Rautava P. Gender differences in myocarditis: a nationwide study in Finland. Eur Heart J. 2013;34(suppl 1):3505.
   Google Scholar
• CDC. Myocarditis and pericarditis considerations: cDC; [ updated 29/09/22; cited 2022 Nov 22]. Available from: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html
   Google Scholar
• Kozma GT, Shimizu T, Ishida T, et al. Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals. Adv Drug Deliv Rev. 2020;154-155:163–175.
   PubMed Web of Science ®Google Scholar
• Carreno JM, Singh G, Tcheou J, et al. mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations. Vaccine. 2022 Oct 6;40(42):6114–6124. DOI:10.1016/j.vaccine.2022.08.024
   PubMed Web of Science ®Google Scholar
• Ju Y, Lee WS, Pilkington EH, et al. Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine. ACS Nano. 2022 Aug 23;16(8):11769–11780. DOI:10.1021/acsnano.2c04543
   PubMedGoogle Scholar
• McMahon DE, Amerson E, Rosenbach M, et al. Cutaneous reactions reported after moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol. 2021 Jul;85(1):46–55.
   PubMed Web of Science ®Google Scholar
• Schulz JB, Berlit P, Diener HC, et al. COVID-19 vaccine-associated cerebral venous thrombosis in Germany. Ann Neurol. 2021 Oct;90(4):627–639.
   PubMed Web of Science ®Google Scholar
• Patone M, Mei XW, Handunnetthi L, et al. Risk of myocarditis after sequential doses of COVID-19 vaccine and SARS-CoV-2 infection by age and sex. Circulation. 2022 Sep 6;146(10):743–754. DOI:10.1161/CIRCULATIONAHA.122.059970
   PubMed Web of Science ®Google Scholar